# PT-141 FAQ: Bremelanotide, Mechanism, Dosage, and Tolerability Questions

> PT-141 FAQ: what it is, whether it equals bremelanotide, how it works, the approved dose, the half-life, and how it differs from PDE-5 inhibitors. Direct, cited answers.

Direct answers to the most common PT-141 questions, cited to the studies and the label where a number is involved.

## What is PT-141?

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin MC3R/MC4R receptors [1]. It is FDA-approved (2019) only for HSDD in premenopausal women; all other uses are off-label [6].

## What is PT-141 peptide?

It is a seven-amino-acid cyclic peptide — the cyclic lactam analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) [1]. The ring structure makes it more stable than linear melanocortin peptides, which is part of why it is dosable as a subcutaneous injection [6].

## What does the PT-141 peptide do?

It activates melanocortin MC3R/MC4R receptors in the hypothalamus and limbic system, engaging brain circuits for sexual desire and arousal rather than acting on blood flow the way PDE-5 inhibitors do [1]. A human fMRI study showed it increased reported desire for up to 24 hours [5].

## What is PT-141 used for?

Its single FDA-approved use is acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. Use in men, for erectile dysfunction, or in postmenopausal women is off-label and, for the male/erectile setting, still investigational [1].

## Is PT-141 the same as bremelanotide?

Yes. PT-141 is the development and research designation; bremelanotide is the international nonproprietary name (INN) for the same molecule — the melanocortin receptor agonist approved for HSDD [6]. They are two names for one compound, `CAS 189691-06-3` [1].

## What is bremelanotide?

Bremelanotide is the approved-drug name for PT-141: a melanocortin MC3R/MC4R agonist approved in `June 2019` (`NDA 210557`) as a `1.75 mg` subcutaneous as-needed injection for HSDD in premenopausal women [6].

## How does PT-141 work?

It stimulates melanocortin MC4R (and MC3R) receptors in hypothalamic circuits such as the medial preoptic area, engaging dopaminergic pathways tied to sexual motivation [1]. An fMRI study showed MC4R agonism altered brain processing of erotic stimuli and increased desire for up to `24 hours` [5].

## What receptors does PT-141 act on?

Chiefly the melanocortin 4 receptor (MC4R), with secondary MC3R activity, concentrated in central nervous system circuits [1]. Peripheral MC1R activation underlies the hyperpigmentation seen with repeated dosing [6].

## Does PT-141 work through the brain or through blood flow?

Through the brain. Unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle, PT-141 works centrally on the neural circuitry of sexual desire and arousal [1]. The human fMRI evidence shows a central processing change, not a vascular one [5].

## What is a melanocortin receptor agonist?

A compound that activates one or more of the five melanocortin receptors (MC1R-MC5R) [1]. PT-141 targets the central MC3R/MC4R subtypes, which is how it influences sexual desire [1].

## Does PT-141 increase testosterone?

No. A common misconception is that PT-141 raises testosterone or acts through the HPG axis. It acts centrally on melanocortin receptors and does not directly raise testosterone, and it is not a PDE-5 inhibitor [11].

## How is PT-141 different from PDE-5 inhibitors?

PDE-5 inhibitors work peripherally on blood vessels to support erection; PT-141 works centrally in the brain on melanocortin circuits governing desire and arousal [1]. The mechanisms are distinct, which is why a combination approach is being investigated for erectile dysfunction [14].

## What is the PT-141 dosage?

Reported as a finding, not a recommendation: the approved label specifies `1.75 mg` subcutaneously, as needed at least `45 minutes` before anticipated activity, with no more than one dose per `24 hours` and no more than `8` doses per month [6].

## How much PT-141 should I take?

This site does not recommend a dose for any individual. The studied and approved amount is `1.75 mg` subcutaneous as-needed in the HSDD trials [6]; any use is a clinical decision made with a prescriber for the approved indication.

## How much PT-141 to inject?

As a research and label finding only: the approved subcutaneous dose studied was `1.75 mg` per administration, capped at one dose in `24 hours` [6]. Phase 2 dose-finding evaluated `0.75`, `1.25`, and `1.75 mg` [6].

## What is the PT-141 dosage for women?

In premenopausal women with HSDD, the approved and studied dose is `1.75 mg` subcutaneous, as needed, no more than once per `24 hours` and no more than `8` times per month [6]. Reported as a trial and label finding, not a personal protocol [3].

## How do you reconstitute PT-141?

The approved finished product is a pre-formulated single-dose subcutaneous injection, so the labeled drug is not reconstituted by the patient [6]. Material sold as "PT-141 research chemical" is for laboratory use only and is not the approved drug; this site gives no preparation protocol for human use.

## How do you take PT-141?

In the trials and on the label, bremelanotide was self-administered as a subcutaneous injection (abdomen or thigh) as needed at least `45 minutes` before anticipated activity [6]. Described here as a study and label finding only.

## How often can you take PT-141?

The label limits dosing to no more than one `1.75 mg` dose per `24 hours` and no more than `8` doses per month [6]. The `52-week` extension study used the same as-needed schedule over a year [4].

## What is the approved bremelanotide dose?

`1.75 mg` subcutaneously, as needed, with a maximum of one dose per `24 hours` and `8` doses per month, per the US prescribing information for the HSDD indication in premenopausal women [6].

## How long does PT-141 last?

Its terminal half-life is about `2.7 hours` (range `1.9-4.0 h`) after subcutaneous dosing per the label, with median Tmax around `0.5-1.0 hour` [6]. In an fMRI study, MC4R agonism increased reported sexual desire for up to `24 hours` [5].

---

A precision-metrology readout of the bremelanotide record — each measured value logged to its study and tagged in-spec or disputed, the effect-size debate kept beside the number it qualifies and the field reports fenced off the calibrated panel; no clinic behind the instrument and nothing here dosed, dispensed, or sold.